/ /

  • linkedin
  • Increase Font
  • Sharebar

    B + L places focus on innovation in pharma, surgical, vision care


    20 new instruments

    The surgical platform is adding more than 20 new instruments in 2017, she continued. Surgeons can expect new devices and technologies, such as the Clarisert preloaded aspheric IOL and a capsular tension ring, all awaiting clearance by the FDA. Also, new are the Stellaris Elite System for cataract and retina surgery and Vitesse Vitrectomy System (all FDA approved in April 2017).

    On the pharmaceutical side, look for new data from phase II trials for a novel transscleral iontophoresis, drug-delivery system. The system is being developed under license from EyeGate Pharma and uses low-level, electrical current to deliver precise doses of ophthalmic pharmaceuticals directly into the eye without the burden of drops or injections.

    Current work suggests that ocular iontophoresis is capable of delivering substantially higher drug concentrations than traditional topical applications, which can lead to greater bioavailability and more sustained therapeutic effect while reducing the frequency of dosing.

    A phase III clinical trial of a corticosteroid for anterior uveitis produced the same rate of clinical response using just 2 treatments compared to a minimum of 154 topical treatments using corticosteroid drops over a 4-week period.

    New glaucoma drug

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results